{"id":428936,"date":"2019-09-17T13:00:01","date_gmt":"2019-09-17T13:00:01","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=428936"},"modified":"2019-09-17T13:00:01","modified_gmt":"2019-09-17T13:00:01","slug":"creative-biolabs-provides-highquality-antidrug-abs-and-antiab-adcs-in-stock","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/creative-biolabs-provides-highquality-antidrug-abs-and-antiab-adcs-in-stock_428936.html","title":{"rendered":"Creative Biolabs Provides High-quality Anti-drug Abs and Anti-Ab ADCs in Stock"},"content":{"rendered":"

New York, US, September 17, 2019 <\/strong>As an international antibody provider specialized in the antibody-drug conjugates field for over 10 years, Creative Biolabs insists on customer-centered services all the time to provide global clients with a series of highly efficient Anti-drug Abs and Anti-Ab ADCs in stock, thereby greatly saving the time and costs.<\/p>\n

Consisting of a monoclonal antibody, a toxic payload and a chemical linker, antibody-drug conjugates <\/a>(ADCs) are regarded as a powerful immunotherapy that can accurately eliminate cancers without damaging normal tissues.<\/p>\n

However, their enormously potent toxins pose a challenge for researchers to develop the corresponding antibodies before the animal immunization and clinical trials. For the sake of a more competent method to facilitate the PK and safety evaluation of newly developed ADCs, Creative Biolabs has raised a series of antibodies, collectively anti-drug Abs<\/a>, against ADC toxin antigens including MMAE, MMAF, DM1, DM4, Calicheamicin, Duocarmycin…<\/p>\n

Partial List of the anti-drug Ab products in stock:<\/strong><\/p>\n

Anti-vc-PAB-MMAE polyclonal antibody (ADC-AD-001)<\/p>\n

Anti-vc-PAB-MMAE monoclonal antibody (ADC-AD-002)<\/p>\n

Anti-MMAF polyclonal antibody (ADC-AD-003)<\/p>\n

Anti-MMAF monoclonal antibody (ADC-AD-004)<\/p>\n

Anti-MMAE\/MMAF monoclonal antibody (clone m1) (ADC-AD-005)<\/p>\n

Anti-MMAE\/MMAF monoclonal antibody (clone m2) (ADC-AD-006)<\/p>\n

 <\/p>\n

In addition to a comprehensive list of Anti-Drug Abs, a series of Anti-Ab ADC products are also provided for screening of ADC-suitable internalizing antibodies under “load-bearing” conditions, including essential proteins (either Protein A or Protein G) or secondary antibodies that interact with the certain region of a monoclonal antibody pre-loaded with toxins. With the help of Anti-Ab ADCs<\/a> products from Creative Biolabs, the desired antibody will be identified when enhanced target cell death is observed due to the internalized toxin.<\/p>\n

 <\/strong><\/p>\n

Partial List of the Anti-Ab ADC products in stock:<\/strong><\/p>\n

Protein G-VC-MMAE ADC<\/p>\n

anti-MIgG (Fc)Fab-N-DM1 ADC<\/p>\n

anti-MIgG (Fc)Fab-C-MMAE ADC<\/p>\n

anti-MIgG (Fc)-C-MMAE ADC<\/p>\n

anti-HIgG (Fab)-N-DM1 ADC<\/p>\n

anti-HIgG (Fab)-C-MMAE ADC<\/p>\n

anti-HIgG (Fc)Fab-N-DM1 ADC<\/p>\n

anti-HIgG (Fc)Fab-C-MMAE ADC<\/p>\n

 <\/p>\n

Not only in stock ADC products, Creative Biolabs also offers a variety of customized ADCs generated by different combinations of antibodies that target a wide range of cancer surface antigens and payload drugs conjugated via various linkers. Experienced scientists will help clients select the most suitable products for ADC projects. More information can be reached at https:\/\/www.creative-biolabs.com\/adc\/<\/a>.<\/p>\n

 <\/p>\n

About Creative Biolabs<\/strong><\/p>\n

With more than a decade of exploration and expansion, Creative Biolabs provides current research and service capacity that covers the entire new drug discovery and development pipeline, ranging from early discovery, pre-clinical evaluations, cGMP manufacturing, to clinical trials. As an international cooperation, Creative Biolabs established offices all around the globe with more than 200 well-trained full-time scientists and technicians, who work closely with customers and research partners to develop new medicines for a better, healthier world. After years of pursuit for perfection, Creative Biolabs has established leadership in targeted immunotherapy and antibody-drug conjugate (ADC) development. They offer customers comprehensive one-stop-shop of all aspects in ADC research and evaluation, ranging from antigen selection, antibody production\/optimization, payload-linker synthesis, ADC conjugation, to various stages of ADC characterization and pre-clinical evaluation.<\/p>\n

 <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Creative Biolabs<\/a>
Contact Person:<\/strong> Candy Swift
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 1-631-619-7922
Address:<\/strong>45-1 Ramsey Road
City:<\/strong> Shirley
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.creative-biolabs.com\/adc\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

New York, US, September 17, 2019 As an international antibody provider specialized in the antibody-drug conjugates field for over 10 years, Creative Biolabs insists on customer-centered services all the time to provide global clients with a series of highly efficient … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,420,411,404],"tags":[],"class_list":["post-428936","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-Technology","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/428936","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=428936"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/428936\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=428936"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=428936"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=428936"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}